CHANDAN Q2 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Chandan Healthcare targets revenue growth with the diagnostic business expected to grow faster than the pharmacy business, shifting the revenue mix towards diagnostics (currently 60-40, expected up to 80-20 in 3 years).
- Plans to open 100 new labs in the next 2.5-3 years, with 2-3 labs starting every month and 2-3 comprehensive diagnostic centers annually.
- Expansion across 17 states, including major cities like Mumbai, Kolkata, and Chandigarh with new lab facilities.
- Exclusive 5-year partnership with Jeena Sikho to provide diagnostic services to their 50 hospitals and 150+ clinics across 17 states, expected to contribute Rs. 25-50 crore per year.
- Franchise model expansion targeting 1,000+ new franchise collection points to increase reach in Tier 1, 2, 3 cities.
- EBITDA and net profit growth targets are over 20%-25% annually with an aim to maintain or exceed a consolidated EBITDA margin of 35% by FY'26.
- IPO planned for FY'27-28 enabled by strong growth and profitability.
See what CHANDAN management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company does not anticipate requiring additional debt or equity for its expansion plans in the near future.
- Currently, they have enough funds to support their growth for the next 2.5 years.
- Future fundraising might be considered only if a significant acquisition opportunity arises.
- The ongoing expansion plan for 100 labs and 8-9 major centers is expected to be funded without needing extra capital.
- They are undertaking a preferential share issue of Rs. 104 crore, with contributions from strategic investors, promoters, and company insiders to support ambitious expansion projects.
See what CHANDAN management said on order book — free account, 30 seconds.
Capex plans
Yes- Chandan Healthcare is investing in setting up a dedicated molecular genome lab at the Delhi facility for advanced genetics and molecular testing.
- Recently secured prime real estate in Mumbai, Chandigarh, and Calcutta for new major processing laboratories to increase capacity and reduce logistics cost.
- Planning to establish 100 new strategically located collection and processing laboratories across 17 states within 2-3 years.
- Launching over 1,000 new franchise collection points in Tier 1, 2, and 3 cities across 17 states.
- Capital investment per lab outside Jeena Sikho's hospital is approximately Rs. 50 lakhs (including renovation, security, rental).
- Labs inside Jeena Sikho require about Rs. 30 lakhs investment in machines.
- No significant additional debt or equity expected for expansion for next 2 years; raised Rs. 104 crore through preferential shares for expansion.
- A 250-bed hospital is planned in Gorakhpur with an MOU; construction timeline is about 2 years.
- IPO planned for April 2027, post achieving 90% bed occupancy and scaling to ~850 beds.
Track CHANDAN — get its next earnings analysis in your feed
Margin guidance
Category 1- Chandan Healthcare targets a net profit and EBITDA growth of more than 20%-25% year-on-year consistently.
- The company aims to maintain or exceed an EBITDA margin of around 35% by the end of FY'26.
- Diagnostic business EBITDA margin is strong at 34.22%, contributing to overall margin expansion.
- Expansion plans include opening 35-40 labs annually, 100 labs targeted in 3 years, aiding revenue and profit growth.
- Partnership with Jeena Sikho expected to generate Rs. 25-50 crores annually, with healthy margins (~80%) contributing positively to earnings.
- Pharmacy EBITDA expected to improve from 5.2% to over 10% in the next 6 months, supporting overall profitability.
- IPO planned in April 2027 to support further growth and consolidation.
- Continuous investment in franchise and comprehensive diagnostic centers to fuel sustained earnings growth.
Order book
- The company is aggressively expanding its diagnostic business with plans to open 2-3 labs every month, targeting over 100 labs in the next 2.5 to 3 years.
- Currently, 8 comprehensive diagnostic centers are operational or about to start by end of FY'26.
- Space has already been taken for labs in Mumbai, Kolkata, and Chandigarh.
- The company is also expanding via franchise with plans for over 1,000 franchises across 17 states.
- The partnership with Jeena Sikho covers collections from 34 units initially, with more to come as Jeena Sikho plans 350 hospitals and clinics in 3 years.
- MOU to add 250 beds in Gorakhpur hospital within 2 years.
- IPO planned in FY 2027-28, with capacity utilization expected to reach 90% by then.
- No immediate requirement for additional debt or equity in the next 2 years for expansion.
How does CHANDAN rank vs peers in Healthcare Services?
Pro featureHow does CHANDAN rank in Healthcare Services?
Compare CHANDAN against every Healthcare Services company (Q2 FY26) on revenue, margins and earnings-call signals.
Continue your research
What CHANDAN's management said in earlier quarters
Others in Healthcare Services this season
- Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
- Health X Platform Ltd (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
- Shalby Ltd (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…